Revolutionary Findings from kidneyintelX.dkd Research
Exciting new results presented at ASN Kidney Week highlight kidneyintelX.dkd as a benchmark in chronic kidney disease (CKD) precision medicine.
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a renowned precision-medicine diagnostics company focused on kidney health, recently announced significant findings published in Diabetes Care, a prestigious journal within the diabetes community. The publication underscores kidneyintelX.dkd, recognized as the only FDA-approved and Medicare-reimbursed prognostic tool for assessing early-stage CKD risk.
The pivotal study analyzed data from 2,954 patients sourced from notable clinical trials, including CANVAS and CREDENCE. These trials represent the entire intended-use population for kidneyintelX.dkd and have provided critical insights into CKD progression and management.
Key Insights from the Study
The findings revealed remarkable enhancements in CKD risk prediction thanks to kidneyintelX.dkd:
- Enhanced CKD Risk Prediction: The tool significantly improved risk stratification across KDIGO guideline categories, offering a more precise evaluation of CKD progression and potential kidney failure.
- Actionable Treatment Guidance: The study found that patients identified as moderate or high risk, when treated with frontline SGLT2 inhibitors, exhibited a significant reduction in risk levels after one year. High-risk patients showed a twofold likelihood of risk improvement compared to those who did not receive treatment.
The authors concluded that kidneyintelX.dkd facilitates the identification of patients who stand to gain the most from therapy, paving the way for personalized and risk-based care strategies.
Expert Commentary on the Impact
Associate Professor Brendon Neuen from The George Institute for Global Health in Sydney, a respected authority in cardio-kidney-metabolic health, shared his insights:
"In light of the breakthroughs in therapies aimed at mitigating kidney function decline, we are at a pivotal moment for implementing risk-based strategies in CKD. Utilizing novel biomarkers like those present in kidneyintelX.dkd provides a promising approach to enhance personalized care and reduce risks of adverse outcomes."
Dr. Neuen also serves as Program Lead for Renal & Metabolic and Director of Kidney Trials at Royal North Shore Hospital.
Showcasing kidneyintelX.dkd at ASN Kidney Week 2025
During the ASN Kidney Week held in Houston, Renalytix presented three crucial abstracts that emphasized the real-world applications and significant performance advantages of kidneyintelX.dkd:
1. Implementation in a Large Integrated Health System: Demonstrated a scalable framework for deploying kidneyintelX.dkd to promote sustained adoption and enhance patient care management across a major US health network.
2. Decision-Impact Study in Community Practice:
- 87% of patients expressed a better understanding of their kidney health risks.
- 98% stated that the test helped them recognize the importance of maintaining kidney health.
- 86% of physicians noted that kidneyintelX.dkd had a direct effect on their care decisions.
3. Superior Prediction vs. KFRE: The data revealed that kidneyintelX.dkd outperformed the Kidney Failure Risk Equation (KFRE) in forecasting kidney function decline and failure among patients with diabetic kidney disease, showcasing its reliability, particularly in earlier stages.
Setting a New Paradigm in CKD Precision Medicine
Throughout various clinical trials and real-world applications, kidneyintelX.dkd has consistently showcased “incremental value” as an integral component of precision medicine initiatives aimed at CKD. These findings endorse its transformative potential within integrated care management, striving for notable enhancements in both patient experience and health outcomes.
The Global Impact of Chronic Kidney Disease
Chronic Kidney Disease represents an ongoing global health crisis, affecting an estimated 850 million people worldwide. In the US alone, it is believed that over 35 million adults are impacted, with the vast majority remaining unaware of their condition. This has significant implications for healthcare expenditure, with Medicare spending exceeding $130 billion yearly on the management of kidney disease.
About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an innovative diagnostics company leveraging artificial intelligence to enhance the clinical management of kidney disease, aiming to optimize patient health outcomes. Their FDA-approved kidneyintelX.dkd is currently available for commercial use in the United States.
To explore more about Renalytix, visit renalytix.com, and for comprehensive details about kidneyintelX.dkd, check kidneyintelx.com.
Frequently Asked Questions
What is kidneyintelX.dkd?
kidneyintelX.dkd is the only FDA-approved prognostic test for assessing the risk of chronic kidney disease.
What are the main benefits of using kidneyintelX.dkd?
This diagnostic tool enhances risk prediction, provides actionable treatment guidance, and helps identify patients likely to benefit from targeted therapies.
How does kidneyintelX.dkd impact treatment decisions?
The test influences physicians' decisions by providing clear insights into a patient's kidney health and associated risks.
Why is CKD considered a global health crisis?
Chronic Kidney Disease affects millions globally, with many unaware of their condition, leading to substantial healthcare costs and adverse health outcomes.
Where can I find more information about Renalytix?
Further information about Renalytix and their offerings can be found on their official website at renalytix.com.
